Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its second-quarter earnings call.

Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per ...

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

CFO Ben Taylor confirmed they finished Q2 with $533 M in the bank and expect to keep burn under $390 M next year. Even better, they're targeting over $100 M in partnership inflows by the end of ...

Before market open on Tuesday, Recursion Pharmaceuticals (RXRX 2.27%) published its latest set of quarterly earnings and business update.

Full transcript - Recursion Pharmaceuticals Inc (RXRX) Q2 2025: Chris Gibson, Co-Founder and CEO, Recursion Pharmaceuticals: Recursion’s q two twenty twenty five earnings call.

Key PointsGAAP revenue surpassed estimates by 24.9% in Q2 2025, driven by milestone payments, including $7 million from Sanofi.

Florida python hunters Zach Hoffman, Jan Gianello and Justice Sargood caught a massive Burmese python in the Everglades on May 31, 2025.

Recursion, Exscientia, and AI drug discovery’s moment of truth Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger.

Reptile Hunter Joseph Hart tells 'Fox & Friends Weekend' about giving a second chance to a massive 16-foot python discovered in downtown Los Angeles.